Cargando…

The mutagenic activity of razoxane (ICRF 159): an anticancer agent.

The mutagenic activity of razoxane (ICRF 159) was studied using the Salmonella/microsome assay and rodent bone-marrow micronucleus and metaphase assays. Razoxane (up to 5000 micrograms/plate) did not cause an increase in the mutation frequency in the Salmonella/microsome assay. In the mouse micronuc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albanese, R., Watkins, P. A.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1985
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977223/ https://www.ncbi.nlm.nih.gov/pubmed/3904803

Ejemplares similares

in vitro effects of ICRF 159.
por: Hellmann, K., et al.
Publicado: (1973)

Proceedings: Analysis of the antimetastatic action of the antimitotic agent ICRF 159.
por: Hellmann, K., et al.
Publicado: (1974)

Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma.
por: Zwilling, B. S., et al.
Publicado: (1981)

Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.
por: Pimm, M. V., et al.
Publicado: (1975)

The effects of ICRF-154 in combination with other anticancer agents in vitro.
por: Kano, Y., et al.
Publicado: (1992)

Razoxane-induced polyploidy.
por: Taylor, I. W., et al.
Publicado: (1978)

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
por: Davies, S. L., et al.
Publicado: (1997)

Reduction of daunomycin toxicity by razoxane.
por: Wang, G., et al.
Publicado: (1981)

ICRF 159-induced cell-cycle perturbation in vitro: its relationship to inhibition of colony-forming ability.
por: Edgar, D. H., et al.
Publicado: (1981)

Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.
por: Taylor, I. W., et al.
Publicado: (1977)

Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro.
por: Taylor, I. W., et al.
Publicado: (1977)

ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
por: Kovacs, C. J., et al.
Publicado: (1979)

ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
por: Kovacs, C. J., et al.
Publicado: (1979)

Combination therapy of a mouse sarcoma using razoxane and electron irradiation.
por: Grimshaw, M. B., et al.
Publicado: (1981)

Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig.
por: Perkins, W. E., et al.
Publicado: (1982)

Reduced survival with radiotherapy and razoxane compared with radiotherapy alone for inoperable lung cancer in a randomised double-blind trial.
por: Newman, C. E., et al.
Publicado: (1985)

The Radiation Response of Sarcomas by Histologic Subtypes: A Review With Special Emphasis Given to Results Achieved With Razoxane
por: Rhomberg, Walter
Publicado: (2006)

Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane
por: Anderson, H, et al.
Publicado: (2003)

Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
por: Jensen, Lars H, et al.
Publicado: (2004)

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
por: Bavlovič Piskáčková, Hana, et al.
Publicado: (2021)

The iCRF Generator: Generating interoperable electronic case report forms using online codebooks
por: de Ridder, Sander, et al.
Publicado: (2020)

Molecular Characterization of Human Papillomavirus Type 159 (HPV159)
por: Marković, Iva, et al.
Publicado: (2021)

Moments, monodromy, and perversity (AM-159): a Diophantine perspective (AM-159)
por: Katz, Nicholas M
Publicado: (2005)

A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms
por: Szikriszt, Bernadett, et al.
Publicado: (2021)

Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
por: Meikle, I., et al.
Publicado: (1996)

DNA binding activity of the proximal C-terminal domain of rat DNA topoisomerase IIβ is involved in ICRF-193-induced closed-clamp formation
por: Kawano, Shinji, et al.
Publicado: (2020)

Mutagenic activity of disinfection by-products.
por: Cognet, L, et al.
Publicado: (1986)

UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study
por: Reimerová, Petra, et al.
Publicado: (2019)

Discussion on P-159 proposal
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1981)

159th RB Meeting
por: CERN. Geneva. Research Board
Publicado: (2002)

A comprehensive structural analysis of the ATPase domain of human DNA topoisomerase II beta bound to AMPPNP, ADP, and the bisdioxopiperazine, ICRF193
por: Ling, Elise M., et al.
Publicado: (2022)

Mutagenic activity of heterocyclic amines in cooked foods.
por: Felton, J S, et al.
Publicado: (1994)

Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events
Publicado: (1994)

Mutagenic activity of concentrated drinking water samples.
por: Wilcox, P, et al.
Publicado: (1986)

Human germinal mutagenic effects in relation to intentional and accidental exposure to toxic agents.
por: Czeizel, A E
Publicado: (1996)

Job burnout in 159 anesthesiology trainees
por: Abut, Yesim Cokay, et al.
Publicado: (2012)

Urine mutagenicity as an indicator of exposure to dietary mutagens formed during cooking of foods.
por: Baker, R S, et al.
Publicado: (1986)

Metabolism and mutagenicity of isoprene.
por: Gervasi, P G, et al.
Publicado: (1990)

Status report of the "dibaryon" experiment S159
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1979)

VLDL-associated mutagenic activity.
por: Gomes, M. I., et al.
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_t497lvt2vocq38sdodlvoq6k5u